Cantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating

Benzinga Newsdesk www.benzinga.com Neutral 72.1%

Neg 0% Neu 72.1% Pos 0%

Cantor Fitzgerald initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Overweight rating.

Comments

No comments yet. Be the first!